Research programme: antibody diagnostics and therapeutics - Immunomedics

Drug Profile

Research programme: antibody diagnostics and therapeutics - Immunomedics

Alternative Names: (14)-3s; (19)-3s; (E1)-3s; (M1)-3s; 20-(74)-(74) antibody; 20-2b; 74-(20)-(20) antibody; Anti-CD19 antibodies; anti-CD20/CD74 antibodies; bsMAb; Ck-20-2b; CK-22-(20)-(20); E1.BB.3z-92MI; MAb-Rap; TF 12; TF 3; TF 4; TF 5; Veltuzumab-interferon-α2b conjugate

Latest Information Update: 06 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Bispecific antibodies; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Recombinant fusion proteins; Ribonucleases
  • Mechanism of Action Apoprotein stimulants; Glycoprotein modulators; Ionising radiation emitters; Mitosis inhibitors; Protein synthesis inhibitors; Ribonuclease stimulants; T lymphocyte stimulants; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Gastric cancer; Lymphoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 23 Feb 2017 Immunomedics plans a phase I trial for Cancer with bispecific antibodies
  • 06 Jan 2017 Preclinical development is ongoing in USA for Cancer, Lymphoma, and Solid tumours
  • 12 Dec 2016 Preclinical trials in Breast cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top